Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting

Status:	Terminated
Conditions:	Cardiology
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	21 - Any
Updated:	4/21/2016
Start Date:	March 2014
End Date:	February 2015

To establish the performance characteristics of the Samsung LABGEO IVD-A20 CHF Test in
intended use settings, by comparing test results of the A20 CHF Test with results obtained
from an FDA-cleared comparator assay.

Inclusion Criteria:

- CHF Subjects: 21 years of age or greater, with clinically confirmed CHF or have
presented to the clinical site with signs, symptoms and/or risk factors suggestive of
heart failure.

- Subjects with Potentially confounding comorbidities: Non-CHF subjects 21 years of age
or greater, with potentially confounding comorbidities such as diabetes, renal
insufficiency, hypertension and chronic obstructive pulmonary disease (COPD)

- Healthy Subjects: apparently healthy subjects greater than 45 years of age, with no
prior history of cardiac-related disease.

Exclusion Criteria:

- Apparently healthy subjects with a history of MI, CHF or other cardiac-related
disease;

- Subjects with acute decompensated heart failure currently on nesiritide therapy;

- Subjects having participated in another experimental drug, biologic, or invasive
device study within 30 days prior to signing informed consent for this study, or
enrolled concurrently in any other investigative study; and

- Subjects unable to or refusing to provide written informed consent.

We found this trial at

sites

Manassas Clinical Research Center

Manassas, Virginia 20110

from

Manassas, VA